Haemonetics Corporation
HAEHealthcareNASDAQMedical Devices · Last scanned Oct 26, 2026
Scan Results
Daily timeframeHaemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions. At a $5.39B market cap, Haemonetics Corporation ranks as a mid-cap company within healthcare. The company operates through Plasma, Blood Center, and Hospital segments.
Market Cap
$5.39B
Beta
0.61
P/E (TTM)
57.25
P/E (Fwd)
20.51
EPS (TTM)
$2.07
EPS (Fwd)
$5.78
ROE
11.2%
ROA
6.6%
Cash
$224.5M
Total Debt
$1.17B
Free CF
$312.8M
52W Change
131.4%
Annual Financials
Cash vs Debt
Where HAE stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, HAE finished 47.82% above its 150-day moving average ($80.32) and 54.27% above its 200-day moving average ($76.96). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is HAE overbought or oversold?
At the October 20, 2026 close, HAE's RSI(14) was 70.7, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $224.5M in cash, though total debt stands at $1.17B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow comes in at $312.8M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of 11.2% points to decent capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 6.6% suggests reasonable efficiency in deploying the company's asset base. Revenue has been uneven over recent years, ranging from $1.17B to $1.33B.
The relatively low beta of 0.61 suggests HAE is a less volatile holding compared to the broader index. The debt-to-cash ratio suggests meaningful leverage on the balance sheet, a factor worth monitoring if credit conditions tighten. The elevated P/E ratio means the stock is priced for significant future growth. If earnings disappoint, the price correction could be sharp. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Haemonetics Corporation's trajectory.